Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 200… Read more
Whitehawk Therapeutics, Inc. (WHWK) - Total Assets
Latest total assets as of September 2025: $167.02 Million USD
Based on the latest financial reports, Whitehawk Therapeutics, Inc. (WHWK) holds total assets worth $167.02 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Whitehawk Therapeutics, Inc. - Total Assets Trend (2019–2024)
This chart illustrates how Whitehawk Therapeutics, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Whitehawk Therapeutics, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Whitehawk Therapeutics, Inc.'s total assets of $167.02 Million consist of 87.2% current assets and 12.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 40.8% |
| Accounts Receivable | $5.90 Million | 8.4% |
| Inventory | $5.31 Million | 7.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Whitehawk Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Whitehawk Therapeutics, Inc.'s current assets represent 87.2% of total assets in 2024, a decrease from 97.9% in 2019.
- Cash Position: Cash and equivalents constituted 40.8% of total assets in 2024, down from 95.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 8.4% of total assets.
Whitehawk Therapeutics, Inc. Competitors by Total Assets
Key competitors of Whitehawk Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Whitehawk Therapeutics, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Whitehawk Therapeutics, Inc. generates 0.37x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Whitehawk Therapeutics, Inc. is currently not profitable relative to its asset base.
Whitehawk Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 16.76 | 4.89 | 0.62 |
| Quick Ratio | 16.76 | 4.54 | 0.62 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $155.19 Million | $ 61.50 Million | $ -11.37 Million |
Whitehawk Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Whitehawk Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.85 |
| Latest Market Cap to Assets Ratio | 1.07 |
| Asset Growth Rate (YoY) | -46.9% |
| Total Assets | $70.32 Million |
| Market Capitalization | $74.94 Million USD |
Valuation Analysis
Above Book Valuation: The market values Whitehawk Therapeutics, Inc.'s assets above their book value (1.07 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Whitehawk Therapeutics, Inc.'s assets decreased by 46.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Whitehawk Therapeutics, Inc. (2019–2024)
The table below shows the annual total assets of Whitehawk Therapeutics, Inc. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $70.32 Million | -46.90% |
| 2023-12-31 | $132.42 Million | -28.12% |
| 2022-12-31 | $184.24 Million | +16.67% |
| 2021-12-31 | $157.91 Million | +738.83% |
| 2020-12-31 | $18.82 Million | +13.00% |
| 2019-12-31 | $16.66 Million | -- |